David V. Goeddel, Ph.D.

Tim Kutzkey, Ph.D.

Peter Svennilson

David Baltimore, Ph.D.

Michael S. Brown, M.D.

Joseph L. Goldstein, M.D.

Tom Maniatis, Ph.D.

Roger Perlmutter, M.D., Ph.D.

James Evangelista

Sue Murakami

Grant Heidrich

NGM uses a combination novel experimental approaches to exploit emerging human biology for the development of novel therapies for metabolic and cardiovascular disease. Initially, the Company will focus on the gastrointestinal endocrine system and stem cell biology with a view toward identifying novel factors implicated in type 2 diabetes.

NGM Biopharmaceuticals, Inc.

South San Francisco, CA

Constellation is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science involving selective regulators that are critical to controlling gene expression. While the Company is initially focused on oncology, its technology platform will likely be applicable to other therapeutic areas, including autoimmune, inflammatory and neurological diseases.

Constellation Pharmaceuticals, Inc.

Cambridge, MA

Immune Design is a new generation vaccine company built on emerging understanding of the role of dendritic cells in determining an effective immune response. The Company is employing improved adjuvants and novel technologies that target and control dendritic cells in an unprecedented manner. This approach could create an entirely new generation of prophylactic and therapeutic vaccines for cancer and infectious diseases and extend the coverage of current vaccines.

Immune Design Corp.

Seattle, WA

Igenica is dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. The Company has developed two unique technology platforms, which collectively offer a function-orientated screening strategy to systematically identify new tumor antigens and effective monoclonal antibody drug candidates.

Igenica, Inc.

Burlingame, CA

Aragon’s recent discoveries show that the biology of hormone resistant cancers can be overcome through the creation of a new class of nuclear receptor targeting drugs, opening the door to a pipeline of new anti-endocrine therapies. The Company’s approach will produce drugs that are mechanistically distinct from therapies that are either in the clinic or currently being developed.

Aragon Pharmaceuticals, Inc.

San Diego, CA

Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon was spun out of Aragon Pharmaceuticals, Inc. The lead compound in Seragon’s SERD program, ARN-810, is currently being evaluated in a Phase I trial for ER+ metastatic breast cancer.

Seragon Pharmaceuticals, Inc.

San Diego, CA

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes, permitting the inhibition or enhancement of protein production. The Company’s lead program, Ataluren (PTC124), is the first investigational new drug designed to enable the formation of a functioning protein in patients with genetic disorders due a nonsense mutation. Ataluren is currently in advanced clinical development for multiple indications, including cystic fibrosis and Duchenne muscular dystrophy.

PTC Therapeutics, Inc.

South Plainfield, NJ

Founded by Dr. Steven L. McKnight, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action.

Peloton Therapeutics, Inc.

Dallas, TX

Nurix is focused on the discovery and development small molecule modulators of ubiquitin ligases for the treatment a broad range of human disorders. The Company leverages a novel allosteric drug discovery platform which offers unique inroads to this previously intractable class of therapeutic targets.


San Francisco, CA